__timestamp | Agios Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 19120000 | 59644696 |
Thursday, January 1, 2015 | 35992000 | 79541000 |
Friday, January 1, 2016 | 50714000 | 98015000 |
Sunday, January 1, 2017 | 71124000 | 103958000 |
Monday, January 1, 2018 | 114145000 | 103654000 |
Tuesday, January 1, 2019 | 132034000 | 128951000 |
Wednesday, January 1, 2020 | 149070000 | 135799000 |
Friday, January 1, 2021 | 121445000 | 149883000 |
Saturday, January 1, 2022 | 121673000 | 220206000 |
Sunday, January 1, 2023 | 119903000 | 265542000 |
Monday, January 1, 2024 | 156784000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Agios Pharmaceuticals, Inc. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, Travere Therapeutics consistently outpaced Agios in SG&A spending, with a notable 123% increase from 2014 to 2023. Agios, on the other hand, saw a 526% rise in the same timeframe, reflecting its strategic investments in growth and development.
By 2023, Travere's SG&A expenses reached approximately 2.66 times that of Agios, highlighting its aggressive expansion strategy. This trend underscores the differing approaches of these companies in navigating the biotech landscape. As the industry evolves, understanding these financial dynamics offers valuable insights into the operational strategies of leading biotech firms.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.